Kiniksa Pharmaceuticals
KNSA
61 hedge funds and large institutions have $224M invested in Kiniksa Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 26 increasing their positions, 14 reducing their positions, and 5 closing their positions.
140% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 5
86% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 14
9% more funds holding
Funds holding: 56 → 61 (+5)
0.67% less ownership
Funds ownership: 87.56% → 86.89% (-0.67%)
24% less capital invested
Capital invested by funds: $295M → $224M (-$71.1M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$3.82M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$3.28M |
| 3 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$2.7M |
| 4 |
BlackRock
New York
|
+$2.16M |
| 5 |
State Street
Boston,
Massachusetts
|
+$1.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$4.88M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$4.36M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$3.11M |
| 4 |
NC
Nexthera Capital
New York
|
-$1.22M |
| 5 |
D.E. Shaw & Co
New York
|
-$1.07M |
KNSA Hedge Fund Activity: Q2 2019 in Review
61 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Kiniksa Pharmaceuticals (KNSA) for Q2 2019, worth a combined $224M — down 24% from $295M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new KNSA positions and 5 closed out — a net gain of 7 holders — while 26 added to existing stakes and 14 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $3.82M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $4.88M sold.
- 61 institutional investors held Kiniksa Pharmaceuticals (KNSA) as of Q2 2019, up from 56 in Q1 2019.
- Funds reported $224M of Kiniksa Pharmaceuticals stock for Q2 2019, down 24% quarter-over-quarter.
- 12 funds opened new Kiniksa Pharmaceuticals positions in Q2 2019 and 5 closed out, a net change of +7 holders.
- The largest Kiniksa Pharmaceuticals buyer in Q2 2019 was Citadel Advisors, an estimated $3.82M added.
- The largest Kiniksa Pharmaceuticals seller in Q2 2019 was Cormorant Asset Management, an estimated $4.88M sold.
Based on aggregated 13F filings for Q2 2019.